We are live on
!
Find out more
CBIO
Crescent Biopharma
CBIO
CBIO
49 hedge funds and large institutions have $52.1M invested in Crescent Biopharma in 2023 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 17 reducing their positions, and 11 closing their positions.
New
Increased
Maintained
Reduced
Closed
1,155% more call options, than puts
Call options by funds: $389K | Put options by funds: $31K
0.01% less ownership
Funds ownership: 0.55% → 0.54% (-0.01%)
11% less funds holding
Funds holding: 55 → 49 (-6)
16% less capital invested
Capital invested by funds: $61.9M → $52.1M (-$9.84M)
53% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 17
55% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 11
Holders
49
Holders Change
-6
Holders Change %
-10.91%
% of All Funds
0.78%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
8
Reduced
17
Closed
11
Calls
$389K
Puts
$31K
Net Calls
+$358K
Net Calls Change
+$231K
Top Buyers
Top Sellers
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
-$482K |
| 2 |
Two Sigma Advisers
New York
|
-$366K |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$248K |
| 4 |
Truist Financial
Charlotte,
North Carolina
|
-$176K |
| 5 |
Two Sigma Investments
New York
|
-$119K |
